SCHEMBL2493026

SCHEMBL2493026

COc1cccc(O)c1C(=O)NC(C1(c2cccc(F)c2)CCNCC1)S(=O)(=O)N1CCC(O)C1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.34
SLC6A9 P48067 2/20 0.33
CCR8 P51685 1/20 0.33
KCNH2 Q12809 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SOAT1 P35610 2/20 0.32
KDM5A P29375 2/20 0.32
GPR6 P46095 3/20 0.31
ALDH1A1 P00352 2/20 0.31
KCNT1 Q5JUK3 1/20 0.31
CDK1 P06493 1/20 0.31
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
CDK2 P24941 1/20 0.31
PRKCB P05771 1/20 0.31
PRKCA P17252 1/20 0.31
PRKCE Q02156 1/20 0.31
HCRTR2 O43614 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469967 0.84 SOAT1 (0.35) SLC6A9SMN1; SMN2SOAT1ALDH1A1PRKCB
SCHEMBL2493197 0.81 SOAT1 (0.33) CCR8KCNH2SMN1; SMN2SOAT1PRKCB
SCHEMBL2468487 0.81 ALDH1A1 (0.33) CCR3SLC6A9CCR8KCNH2SOAT1
SCHEMBL2471510 0.81 SOAT1 (0.34) CCR3SLC6A9CCR8KCNH2SOAT1
SCHEMBL2471272 0.81 PNLIP (0.34) SMN1; SMN2SOAT1ALDH1A1
SCHEMBL2471385 0.81 SLC6A9 (0.41) SLC6A9SMN1; SMN2ALDH1A1
SCHEMBL2470579 0.79 KMT2A (0.34) CCR3SLC6A9CDK2PRKCBPRKCA
SCHEMBL2492124 0.78 SOAT1 (0.32) CCR3SOAT1ALDH1A1
SCHEMBL2468085 0.78 SOAT1 (0.32) CCR3SOAT1
SCHEMBL2469411 0.78 SMN1; SMN2 (0.34) CCR3CCR8KCNH2SMN1; SMN2SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 CCR3 4826/4885SLC6A9 2351/4885CCR8 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.